Dolutegravir (Tivicay) 1 more important medicine!

Image default
Antiretrovirals CD4 Dolutegravir

Dolutegravir (Tivicay)

Dolutegravir (Tivicay) belongs to the class of antiretroviral drugs known as integrase inhibitors. The drug acts against the integrase protein of HIV, blocking their ability to integrate their genetic code into human cells.

Received marketing approval from the US Food and Drug Administration (FDA) in 2013 and Europe in January 2014 for use by adults and adolescents over 12 years of age.

Dolutegravir is formulated as a 50 mg yellow tablet. The dose of dolutegravir is 50 mg (one tablet) once daily or twice daily if taken with efavirenz, nevirapine, tipranavir or HIV known to be resistant to integrase inhibitors. It can be taken with ours without food.

Dolutegravir is also available as part of a fixed dose combination pill called Triumeq. Look Triumeq for more details.

Clinical trials leading to dolutegravir approval show that the three drug regimens containing the drug are highly effective and well tolerated. Several studies have shown that dolutegravir-based treatment is superior to treatment with darunavir / ritonavir or efavirenz in previously untreated people.

81 / 100 SEO Score

The texts below may interest you!

Hi! Your opinion always matters. Got something to say? Is here! Any questions? We can start here!

This site uses Akismet to reduce spam. Learn how your feedback data is processed.

Automattic, Wordpress and Soropositivo.Org, and I, do everything in our power regarding your privacy. And we are always improving, improving, testing and implementing new data protection technologies. Your data is protected, and I, Claudio Souza, work on this blog 18 hours or day to, among many other things, ensure the security of your information, since I know the implications and complications of past and exchanged publications. I accept the Privacy Policy of Soropositivo.Org Know Our Privacy Policy

%d Bloggers like this: